ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in several solid tumors including brain metastases, but single agent ICIs have failed to improve outcome in recurrent (GBM). This study evaluated the safety of anti-CTLA-4 (IPI) and anti-PD-1 (NIVO) ICIs alone or in combina...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Gilbert, Mark, Zhang, Peixin, Sloan, Andrew, Aldape, Kenneth, Wu, Jing, Rogers, Lisa, Wen, Patrick, Barani, Igor, Iwamoto, Fabio, Raval, Raju, Voloshin, Alfredo, de Groot, John, Won, Minhee, Mehta, Minesh P
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216145/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados